Role of Minimal Residual Disease Monitoring in Adult and Pediatric Acute Lymphoblastic Leukemia

被引：87

作者：

Campana, Dario ^{[1
,2
,3
]}

机构：

[1] St Jude Childrens Res Hosp, Dept Oncol, Memphis, TN 38105 USA

[2] St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA

[3] Univ Tennessee, Hlth Sci Ctr, Memphis, TN 38163 USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2009年 / 23卷 / 05期

关键词：

Acute lymphoblastic leukemia; Minimal residual disease; Flow cytometry; Polymerase chain reaction; Prognosis; STEM-CELL TRANSPLANTATION; POLYMERASE-CHAIN-REACTION; TIME QUANTITATIVE PCR; PRECURSOR-B-ALL; RECEPTOR GENE REARRANGEMENTS; CHILDRENS ONCOLOGY GROUP; CHONDROITIN SULFATE PROTEOGLYCAN; BFM STUDY-GROUP; BONE-MARROW; FLOW-CYTOMETRY;

D O I：

10.1016/j.hoc.2009.07.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Assays that measure minimal residual disease (MRD) can determine the response to treatment in patients with acute lymphoblastic leukemia (ALL) much more precisely than morphologic screening of bone marrow smears. The clinical significance of MRD, detected by flow cytometry or polymerase chain reaction-based methods in childhood ALL, has been established. Hence, MRD is being used in several clinical trials to adjust treatment intensity. Similar findings have been gathered in adult patients with ALL, making MRD one of the most powerful and informative parameters to guide clinical management. This article discusses practical issues related to MRD methodologies and the evidence supporting the use of MRD for risk assignment in clinical trials.

引用

页码：1083 / +

页数：17

共 96 条

[1]

Molecular genetics of acute lymphoblastic leukemia [J].

Armstrong, SA ;

Look, AT .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (26) :6306-6315

[2]

Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: The Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials [J].

Attarbaschi, Andishe ;

Mann, Georg ;

Panzer-Gruemayer, Renate ;

Roettgers, Silja ;

Steiner, Manuel ;

Koenig, Margit ;

Csinady, Eva ;

Dworzak, Michael N. ;

Seidel, Markus ;

Janousek, Dasa ;

Moericke, Anja ;

Reichelt, Carsten ;

Harbott, Jochen ;

Schrappe, Martin ;

Gadner, Helmut ;

Haas, Oskar A. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (18) :3046-3050

[3]

Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL [J].

Bader, P ;

Hancock, J ;

Kreyenberg, H ;

Goulden, NJ ;

Niethammer, D ;

Oakhill, A ;

Steward, CG ;

Handgretinger, R ;

Beck, JF ;

Klingebiel, T .

LEUKEMIA, 2002, 16 (09) :1668-1672

[4]

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL) [J].

Bassan, Renato ;

Spinelli, Orietta ;

Oldani, Elena ;

Intermesoli, Tamara ;

Tosi, Manuela ;

Peruta, Barbara ;

Rossi, Giuseppe ;

Borlenghi, Erika ;

Pogliani, Enrico M. ;

Terruzzi, Elisabetta ;

Fabris, Pietro ;

Cassibba, Vincenzo ;

Lambertenghi-Deliliers, Giorgio ;

Cortelezzi, Agostino ;

Bosi, Alberto ;

Gianfaldoni, Giacomo ;

Ciceri, Fabio ;

Bernardi, Massimo ;

Gallamini, Andrea ;

Mattei, Daniele ;

Di Bona, Eros ;

Romani, Claudio ;

Scattolin, Anna Maria ;

Barbui, Tiziano ;

Rambaldi, Alessandro .

BLOOD, 2009, 113 (18) :4153-4162

[5]

Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;p13) and MLL gene rearrangements [J].

Behm, FG ;

Smith, FO ;

Raimondi, SC ;

Pui, CH ;

Bernstein, ID .

BLOOD, 1996, 87 (03) :1134-1139

[6]

BEISHUIZEN A, 1993, LEUKEMIA, V7, P2045

[7]

BEISHUIZEN A, 1991, LEUKEMIA, V5, P657

[8]

Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features.: A case control study of the International BFM study group [J].

Biondi, A ;

Valsecchi, MG ;

Seriu, T ;

D'Aniello, E ;

Willemse, MJ ;

Fasching, K ;

Pannunzio, A ;

Gadner, H ;

Schrappe, M ;

Kamps, WA ;

Bartram, CR ;

van Dongen, JJM ;

Panzer-Grümayer, ER .

LEUKEMIA, 2000, 14 (11) :1939-1943

[9]

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study [J].

Borowitz, Michael J. ;

Devidas, Meenakshi ;

Hunger, Stephen P. ;

Bowman, W. Paul ;

Carroll, Andrew J. ;

Carroll, William L. ;

Linda, Stephen ;

Martin, Paul L. ;

Pullen, D. Jeanette ;

Viswanatha, David ;

Willman, Cheryl L. ;

Winick, Naomi ;

Camitta, Bruce M. .

BLOOD, 2008, 111 (12) :5477-5485

[10]

Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study [J].

Borowitz, MJ ;

Pullen, DJ ;

Shuster, JJ ;

Viswanatha, D ;

Montgomery, K ;

Willman, CL ;

Camitta, B .

LEUKEMIA, 2003, 17 (08) :1566-1572

← 1 2 3 4 5 6 7 8 9 10 →